Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes (T2DM) and mild hyperglycemia

被引：0
|
作者：
Scherbaum, W. A.
Schweizer, A.
Mari, A.
Nilsson, P. M.
Lalanne, G.
Jauffret, S.
Foley, J. E.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A134 / A134
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
    Scherbaum, W. A.
    Schweizer, A.
    Mari, A.
    Nilsson, P. M.
    Lalanne, G.
    Jauffret, S.
    Foley, J. E.
    [J]. DIABETES OBESITY & METABOLISM, 2008, 10 (08): : 675 - 682
  • [2] Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
    Pi-Sunyer, F. Xavier
    Schweizer, Anja
    Mills, David
    Dejager, Sylvie
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 132 - 138
  • [3] Vildagliptin decreases postprandial chylomicron triglycerides (TGs) in drug-naive patients with type 2 diabetes (T2DM)
    Matikainen, Niina
    Manttari, Sakari
    Schweizer, Anja
    Ulvestad, Anne
    Mills, David
    Dunning, Beth E.
    Foley, James E.
    Taskinen, Marja-Riitta
    [J]. DIABETES, 2006, 55 : A125 - A125
  • [4] Efficacy of vildagliptin in drug-naive patients with type 2 diabetes
    Dejager, S.
    Baron, M. A.
    Razac, S.
    Foley, J. E.
    Dickinson, S.
    Schweizer, A.
    [J]. DIABETOLOGIA, 2006, 49 : 479 - 480
  • [5] Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes (T2DM): Superior efficacy and tolerability with vildagliptin
    Iwamoto, Yasuhiko
    Kashiwagi, Atsunori
    Yamada, Nobuhiro
    Terao, Shinji
    Suzuki, Manabu
    [J]. DIABETES, 2008, 57 : A167 - A167
  • [6] Efficacy and tolerability of vildagliptin added to a sulfonylurea (SU) in patients with type 2 diabetes (T2DM)
    Garber, A. J.
    Camisasca, R.-P.
    Jauffret, S.
    Baron, M. A.
    [J]. DIABETES, 2007, 56 : A134 - A134
  • [7] Empagliflozin Monotherapy Improves Glucose Control in Drug-Naive Patients With Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Eilbracht, Jens
    Delafont, Bruno
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A280 - A280
  • [8] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2014, 63 : A69 - A69
  • [9] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    [J]. ENDOCRINE REVIEWS, 2014, 35 (03)
  • [10] Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM)
    Rosenstock, Julio
    Baron, Michelle A.
    Schweizer, Anja
    Mills, David
    Dejager, Sylvie
    [J]. DIABETES, 2006, 55 : A133 - A133
12345